Roquefort Therapeutics (ROQ) News Today GBX 3.92 +0.02 (+0.59%) (As of 12/20/2024 11:17 AM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsInsider Trades All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Roquefort Therapeutics (LON:ROQ) Shares Down 3.3% - Should You Sell?December 18, 2024 | americanbankingnews.comGlycoMimetics, Inc. (GKO.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comRoquefort Therapeutics says MK cell therapy patent approved in JapanSeptember 24, 2024 | lse.co.ukTG Therapeutics, Inc. (TGTX)August 10, 2024 | finance.yahoo.comRoquefort Therapeutics PLC ROQMay 29, 2024 | morningstar.comEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyApril 26, 2024 | lse.co.ukUK Stocks: Here’s Why Roquefort (ROQ) Share Price is CrashingApril 5, 2024 | msn.comRoquefort celebrates "significant milestones" in cancer researchMarch 11, 2024 | lse.co.ukRoquefort Therapeutics reveals progress with liver and colorectal cancer programmesMarch 11, 2024 | uk.investing.comNBSE NeuBase Therapeutics, Inc.December 21, 2023 | seekingalpha.comRoquefort Therapeutics MK cell programme shows positive resultsNovember 6, 2023 | lse.co.ukRoquefort Therapeutics preparing targets for clinic as eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as it eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patentsAugust 17, 2023 | finance.yahoo.comRoquefort Therapeutics making headway with siRNAAugust 9, 2023 | finance.yahoo.comRoquefort Therapeutics highlights significant progress at AGMJune 29, 2023 | proactiveinvestors.comRoquefort Therapeutics hails significant pre-clinical resultsJune 22, 2023 | proactiveinvestors.comRoquefort Therapeutics Makes Progress on Cancer TreatmentJune 22, 2023 | marketwatch.comRoquefort Therapeutics returns to the market with new study dataJune 16, 2023 | finance.yahoo.comRoquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive ResultsJune 13, 2023 | marketwatch.comRoquefort Therapeutics Resumes Trading After Publishing 2022 ResultsJune 7, 2023 | marketwatch.comRoquefort Therapeutics eyes second half progressJune 5, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardMarch 6, 2023 | proactiveinvestors.comRoquefort Thera Regulatory NewsFebruary 22, 2023 | lse.co.ukRoquefort Therapeutics PLCFebruary 21, 2023 | barrons.comRoquefort Therapeutics inks Randox diagnostic dealFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics demonstrates initial safety in two antibody programmesJanuary 26, 2023 | finance.yahoo.comRoquefort Therapeutics demonstrates safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics cancer drugs enjoy pre-clinical successJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics CEO lays out strategy for 2023January 9, 2023 | proactiveinvestors.comRoquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companiesJanuary 9, 2023 | proactiveinvestors.comRoquefort Therapeutics to present breakthrough RNA cancer study results at key conferenceOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics explains the significance of its "very exciting" cancer drug study resultsOctober 11, 2022 | proactiveinvestors.comStratford-upon-Avon company bought in multi-million pound dealSeptember 21, 2022 | msn.comBiotech firm Oncogeni acquired in £5.5m dealSeptember 20, 2022 | msn.comUK Retailers Drop After August Sales SlumpSeptember 17, 2022 | morningstar.comRoquefort enlists Nobel prizewinner Sir Martin EvansSeptember 16, 2022 | thetimes.co.ukFTSE 100 opens lower as world bank warns of recession.September 16, 2022 | proactiveinvestors.comRoquefort Therapeutics plc (ROQ.L)September 2, 2022 | uk.finance.yahoo.comRoquefort Investments PLC (ROQ)August 20, 2022 | investing.comRoquefort Therapeutics PLC Announces Commencement of Trading on US OTCQB Venture MarketJuly 15, 2022 | finance.yahoo.com Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. ROQ Media Mentions By Week ROQ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROQ News Sentiment▼0.750.60▲Average Medical News Sentiment ROQ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROQ Articles This Week▼10▲ROQ Articles Average Week Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPTI News OBI News ONC News SNG News FAB News IXI News IMM News DEST News PYC News VAL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:ROQ) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
